NRx Pharmaceuticals Announces Data-Lock Of Phase 2b/3 Trial Of NRX-101 In Suicidal Treatment Resistant Bipolar Depression; With Data From This Study And FDA Comment, NRx Becomes Eligible To Receive The Balance Of Its First Milestone Of An Additional $4M From Partners Alvogen, Inc. And Lotus Pharmaceuticals, Inc.
Benzinga Newsdesk - Apr 8, 2024, 8:37AM